美迪醫(yī)療網(wǎng)成揚(yáng)報(bào)道：美國Bristol-Myers Squibb醫(yī)學(xué)影像公司(N. Billerica, MA, USA)從英國Thermocore醫(yī)學(xué)公司(Guildford, UK)獲得了新型冠狀動脈內(nèi)熱成像導(dǎo)管系統(tǒng)的全球所有權(quán)，該系統(tǒng)通過描記冠狀動脈內(nèi)溫度變化差異來檢查易損斑塊。具體交易情況沒有公布。

易損斑塊破裂可以觸發(fā)血凝塊的形成，從而阻斷流向心肌的血流，導(dǎo)致心肌梗塞發(fā)作或者心源性猝死。該導(dǎo)管系統(tǒng)通過將一系列敏感的溫度探頭整合在導(dǎo)管系統(tǒng)的末端，從而獲得冠狀動脈內(nèi)部的熱成像圖譜。通過描記這些溫度變化差異，能夠在斑塊破裂形成血凝塊之前對斑塊進(jìn)行鑒別和定位。

該系統(tǒng)的初期研發(fā)工作是由Thermocore醫(yī)學(xué)公司完成的。而根據(jù)協(xié)議，Bristol-Myers Squibb醫(yī)學(xué)影像公司獲得了在全球范圍內(nèi)研發(fā)、制造以及將Thermocore所擁有的平臺技術(shù)與熱成像導(dǎo)管系統(tǒng)商業(yè)化的權(quán)力。

“Thermocore公司的新技術(shù)平臺是對冠狀動脈內(nèi)易損斑塊進(jìn)行鑒別和診斷的重大突破。”Bristol-Myers Squibb醫(yī)學(xué)影像公司的總裁Cory Zwerling說，“我們希望進(jìn)一步開發(fā)這種前途光明的技術(shù)，使得早期干預(yù)處于危險(xiǎn)的患者以及改善他們的預(yù)后成為可能。”

Bristol-Myers Gets Rights to Thermographic Catheter
 
The worldwide rights to a novel intracoronary thermographic catheter system designed to detect vulnerable plaque by mapping temperature variations inside the coronary arteries have been acquired by Bristol-Myers Squibb Medical Imaging (N. Billerica, MA, USA) from Thermocore Medical Ltd. (Guildford, UK). Financial terms were not disclosed.

When vulnerable plaque ruptures, it can trigger the formation of blood clots that, in turn, can obstruct blood flow to the heart muscle and lead to a heart attack or sudden cardiac death. The catheter system provides a thermal imaging map of the interior of coronary arteries by incorporating a series of sensitive temperature sensors into the distal end of the catheter system. Mapping of these temperature differentials could potentially identify and localize plaque before it ruptures and creates blood clots.

The initial development work on the catheter system was done by Thermocore Medical. Under the agreement, Bristol-Myers Squibb Medical Imaging has the worldwide rights to develop, manufacture, and commercialize Thermocore’s proprietary platform technology and its thermographic catheter system.

“Thermocore’s novel technology platform could represent an important advance in the identification and characterization of vulnerable plaque in the coronary arteries,” noted Cory Zwerling, president, Bristol-Myers Squibb Medical Imaging. “We are looking forward to further defining the potential of this promising technology in hopes of facilitating earlier intervention and improved outcomes for patients at risk.”